MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. TDOC
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Teladoc Health (TDOC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Teladoc Health
NYSE•Healthcare•Health Information Services
$6.28-0.19(-0.03%)Market closed
Market Cap
$1.14B
P/S
0.5x
P/B
0.9x

Teladoc Health, Inc. provides virtual healthcare services worldwide. It operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical services, specialty medical, chronic condition management, and mental health services, as well as technologies and enterprise telehealth solutions for hospitals and health systems. Its BetterHelp segment operates a mental health platform that provides online counselling and therapy services through websites, mobile applications, phones, and text-based interactions by its licensed clinicians. The company offers its products and services under the Teladoc and BetterHelp brands. It serves employers, health plans, hospitals and health systems, insurance companies, and financial services companies, as well as individual members. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. Teladoc Health, Inc. was incorporated in 2002 and is headquartered in New York, New York.

D

How this company scores

WeakMetricSide Score: 40/100

Grade capped at D — Interest coverage below 1× (-9.1x) — earnings cannot cover interest. Strongest: Profitability (17/25); weakest: Growth (6/25).

Profitability17/25
Growth6/25
Balance Sheet & Red Flags7/25
Cash & Earnings Quality10/25
Strengths
Long cash runwayConsistent free cash flowProfit converts from growthNet cash position
Grade capped at D
  • Interest coverage below 1× (-9.1x) — earnings cannot cover interest.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 0.5x5y range 0.4x – 10.8x
P/S 0.5x · below its 20-quarter median

Currently below its 20-quarter median.

P/B · 0.9x5y range 0.7x – 1.8x
P/B 0.9x · near its 20-quarter median

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

FCF consistently trails net income (avg -1.9x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume
Market Cap $1.14B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$2.49B
2Q
Q. Revenue
$606.93M
2Q
TTM EBITDA
$179.59M
3Q
TTM Op. Income
$-186.82M
3Q
Q. Op. Income
$-37.09M
32%
TTM Net Income
$-177.40M
14%
Q. Net Income
$-38.91M
19%
EPS
$-0.21
11%
Shares Out.
$181.03M
7Q
$2.49B in TTM revenue declined 2.1% YoY, reaching $606.93M last quarter. TTM EBITDA of $179.59M and TTM operating income of $-186.82M show growth is flowing through to the bottom line. However, net income is negative at $177.40M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
68.6%
2%
EBITDA Margin
8.9%
45%
Op. Margin
-6.1%
29%
Net Margin
-6.4%
24%
Op. margin of -6.1% is up 2.5% YoY — cost efficiency is improving. Net margin at -6.4% and gross margin of 68.6% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 29% — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
N/A
P/S Ratio
0.5x
24%
P/B Ratio
0.9x
19%
P/S of 0.5x and P/B of 0.9x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$2.76B
7Q
Cash
$774.35M
14%
Long-Term Debt
N/A
6Q
Book Value
$1.31B
7Q
D/E Ratio
N/A
6Q
Debt/EBITDA
0.0
100%

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$64.66M
29%
TTM Free Cash Flow
$253.70M
2Q
FCF Margin
10.2%
2Q
FCF / Net Income
-1.4
2%
TTM FCF of $253.70M on $64.66M in operating cash flow. The FCF / Net Income ratio of -1.4x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General

Revenue Decline

Watch

Revenue has softened, declining in 6 quarters. Watch for further erosion.

Share Dilution

Red Flag

Shares outstanding increased 5.6% — significant dilution, likely from stock compensation or capital raises.